Developed by UCL spinout Autolus, Aucatzyl will be launched imminently across England and Wales. A UK-developed cell therapy ...

At the 2025 Veeva Commercial Summit Europe, experts touted the benefits of AI but stressed the importance of data and ...

Made Scientific and Cellergy Therapeutics have formed a partnership to advance CLG-001 mitochondrial therapy towards in-human ...

Novartis has received approval from the US Food and Drug Administration (FDA) for the Itvisma gene replacement therapy to ...

While the Phase III results confirm prior analyst sentiments, a KOL notes that GLP-1RAs could still show potential in the ...

When a drug product is unstable—whether it is sensitive to light, shear, or temperature—the formulation and sterile filling ...

Lilly breaking through the $1tn market cap ceiling comes as investors have increasingly turned to pharma stocks. The S&P 500 ...

An FDA officer explains the agency’s compliance requirements for importing pharmaceuticals and biologics and processes.

The industry is showing enthusiasm for novel technologies that improve safety and carry innovation potential including in vivo CAR-Ts.

In 2024, the FDA granted a record 63 designations to antibody drug conjugates (ADCs), nearly double the previous high of 35 ...

AstraZeneca has announced a $2bn investment plan to expand its biomanufacturing presence in Frederick, Maryland, US.

Advances in large-volume injectors are enabling faster, more comfortable, at-home treatment. Patient-centric design, ...